Metraipolis › archive › dc_487da0212ce6
Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies — Europe PMC PMID:42440541
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42440541
- DOI
- 10.3389/fendo.2026.1851074
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T06:37:28.246Z
- SHA-256 of the archived text
61f02895a3ad3593cbd6bcdae56ae7b10734068a760821bb63e28aaca68253fa- Stable URL of this page
https://metraipolis.com/documento/dc_487da0212ce6
How to cite
Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies — Europe PMC PMID:42440541 — Europe PMC (en), https://europepmc.org/article/MED/42440541 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_487da0212ce6 (Metraipolis archive dc_487da0212ce6, sha256 61f02895a3ad3593cbd6bcdae56ae7b10734068a760821bb63e28aaca68253fa)
BibTeX
@misc{dc487da0212ce6,
title = {Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies — Europe PMC PMID:42440541},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42440541},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_487da0212ce6; sha256 61f02895a3ad3593cbd6bcdae56ae7b10734068a760821bb63e28aaca68253fa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42440541. Agents can read the archived copy with the MCP tool read_document.